BR112013004750A2 - derivados de quinolina e quinoxalina como inibidores da cinase - Google Patents
derivados de quinolina e quinoxalina como inibidores da cinaseInfo
- Publication number
- BR112013004750A2 BR112013004750A2 BR112013004750A BR112013004750A BR112013004750A2 BR 112013004750 A2 BR112013004750 A2 BR 112013004750A2 BR 112013004750 A BR112013004750 A BR 112013004750A BR 112013004750 A BR112013004750 A BR 112013004750A BR 112013004750 A2 BR112013004750 A2 BR 112013004750A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinoline
- quinoxaline derivatives
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
Abstract
derivados de quinolina e quinoxalina como inibidores da cinase. uma série de derivados de quinolina e quinoxalina que compreendem uma cadeia lateral de etila fluorada, que são inibidores seletivos das enzimas de p13 cinase, não consequentemente de benefício na medicina, por exemplo no tratamento de condições inflamatórias, autoimunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas ou oftálmicas.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1014963.1A GB201014963D0 (en) | 2010-09-08 | 2010-09-08 | Therapeutic agents |
| GB1014963.1 | 2010-09-08 | ||
| GB1101128.5 | 2011-01-21 | ||
| GBGB1101128.5A GB201101128D0 (en) | 2011-01-21 | 2011-01-21 | Therapeutic agents |
| PCT/GB2011/051647 WO2012032334A1 (en) | 2010-09-08 | 2011-09-02 | Quinoline and quinoxaline derivatives as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013004750A2 true BR112013004750A2 (pt) | 2016-08-02 |
| BR112013004750B1 BR112013004750B1 (pt) | 2021-06-15 |
Family
ID=45810169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013004750-0A BR112013004750B1 (pt) | 2010-09-08 | 2011-09-02 | Derivados de quinolina e quinoxalina como inibidores da cinase |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9029392B2 (pt) |
| EP (1) | EP2614061B1 (pt) |
| JP (1) | JP5820882B2 (pt) |
| KR (1) | KR101880280B1 (pt) |
| CN (1) | CN103153996B (pt) |
| AR (1) | AR082799A1 (pt) |
| AU (1) | AU2011300521B2 (pt) |
| BR (1) | BR112013004750B1 (pt) |
| CA (1) | CA2808959C (pt) |
| CL (1) | CL2013000603A1 (pt) |
| CO (1) | CO6680717A2 (pt) |
| CY (1) | CY1116734T1 (pt) |
| DK (1) | DK2614061T3 (pt) |
| EA (1) | EA024162B1 (pt) |
| ES (1) | ES2544289T3 (pt) |
| HK (1) | HK1181754A1 (pt) |
| HR (1) | HRP20150868T1 (pt) |
| HU (1) | HUE025223T2 (pt) |
| IL (1) | IL224841A (pt) |
| MA (1) | MA34600B1 (pt) |
| ME (1) | ME02203B (pt) |
| MX (1) | MX2013002529A (pt) |
| MY (1) | MY162396A (pt) |
| NZ (1) | NZ607966A (pt) |
| PL (1) | PL2614061T3 (pt) |
| PT (1) | PT2614061E (pt) |
| RS (1) | RS54202B1 (pt) |
| SG (1) | SG187924A1 (pt) |
| SI (1) | SI2614061T1 (pt) |
| SM (1) | SMT201500195B (pt) |
| TW (1) | TWI510489B (pt) |
| WO (1) | WO2012032334A1 (pt) |
| ZA (1) | ZA201301751B (pt) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| CN103946226A (zh) | 2011-07-19 | 2014-07-23 | 无限药品股份有限公司 | 杂环化合物及其应用 |
| WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104744435B (zh) * | 2013-12-25 | 2017-03-01 | 上海医药工业研究院 | 喹啉类化合物、其盐、其中间体、制备方法及应用 |
| US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| CA2998469A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| GB201608797D0 (en) * | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| CN108239076B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
| WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2139882B1 (en) | 2007-03-23 | 2013-12-25 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| MX2009009968A (es) | 2007-03-23 | 2009-10-08 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| JP2010522177A (ja) * | 2007-03-23 | 2010-07-01 | アムジエン・インコーポレーテツド | 複素環化合物およびその使用 |
| ES2587738T3 (es) * | 2007-12-21 | 2016-10-26 | Ucb Biopharma Sprl | Derivados de quinoxalina y quinolina como inhibidores de quinasa |
| GB0819593D0 (en) | 2008-10-24 | 2008-12-03 | Ucb Pharma Sa | Therapeutic agents |
| EP2499129B1 (en) * | 2009-11-12 | 2014-07-30 | UCB Pharma, S.A. | Quinoline and quinoxaline derivatives as kinase inhibitors |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
-
2011
- 2011-08-30 AR ARP110103154A patent/AR082799A1/es active IP Right Grant
- 2011-09-02 KR KR1020137008975A patent/KR101880280B1/ko active IP Right Grant
- 2011-09-02 BR BR112013004750-0A patent/BR112013004750B1/pt active IP Right Grant
- 2011-09-02 WO PCT/GB2011/051647 patent/WO2012032334A1/en active Application Filing
- 2011-09-02 RS RS20150538A patent/RS54202B1/en unknown
- 2011-09-02 CA CA2808959A patent/CA2808959C/en active Active
- 2011-09-02 EP EP20110755423 patent/EP2614061B1/en active Active
- 2011-09-02 PT PT117554238T patent/PT2614061E/pt unknown
- 2011-09-02 MY MYPI2013000767A patent/MY162396A/en unknown
- 2011-09-02 EA EA201300317A patent/EA024162B1/ru not_active IP Right Cessation
- 2011-09-02 NZ NZ607966A patent/NZ607966A/en unknown
- 2011-09-02 AU AU2011300521A patent/AU2011300521B2/en active Active
- 2011-09-02 SG SG2013012794A patent/SG187924A1/en unknown
- 2011-09-02 PL PL11755423T patent/PL2614061T3/pl unknown
- 2011-09-02 ES ES11755423.8T patent/ES2544289T3/es active Active
- 2011-09-02 ME MEP-2015-120A patent/ME02203B/me unknown
- 2011-09-02 HU HUE11755423A patent/HUE025223T2/en unknown
- 2011-09-02 US US13/821,294 patent/US9029392B2/en active Active
- 2011-09-02 JP JP2013527681A patent/JP5820882B2/ja active Active
- 2011-09-02 CN CN201180049091.2A patent/CN103153996B/zh active Active
- 2011-09-02 SI SI201130542T patent/SI2614061T1/sl unknown
- 2011-09-02 MA MA35807A patent/MA34600B1/fr unknown
- 2011-09-02 MX MX2013002529A patent/MX2013002529A/es active IP Right Grant
- 2011-09-02 DK DK11755423.8T patent/DK2614061T3/en active
- 2011-09-06 TW TW100132061A patent/TWI510489B/zh active
-
2013
- 2013-02-21 IL IL224841A patent/IL224841A/en active IP Right Grant
- 2013-03-01 CL CL2013000603A patent/CL2013000603A1/es unknown
- 2013-03-07 ZA ZA2013/01751A patent/ZA201301751B/en unknown
- 2013-03-21 CO CO13056775A patent/CO6680717A2/es active IP Right Grant
- 2013-07-30 HK HK13108926.7A patent/HK1181754A1/xx unknown
-
2015
- 2015-08-11 SM SM201500195T patent/SMT201500195B/xx unknown
- 2015-08-13 HR HRP20150868TT patent/HRP20150868T1/hr unknown
- 2015-08-18 CY CY20151100718T patent/CY1116734T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013004750A2 (pt) | derivados de quinolina e quinoxalina como inibidores da cinase | |
| EA201590554A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| TN2018000094A1 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| BR112016029630A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase | |
| MX2012007898A (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| WO2013040251A8 (en) | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| SG10201804952QA (en) | Glucosylceramide synthase inhibitors | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| IN2014DN08385A (pt) | ||
| WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
| MX2015012842A (es) | Prodecimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| MX359209B (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| MX2012014983A (es) | Quinolinas como inhibidores pi3k. | |
| CY1121216T1 (el) | Μεθοδοι για ανακουφιση συμπτωματων πολλαπλης σκληρυνσης βασει συνθεσεων που περιεχουν αποαεκουορινη | |
| TN2013000080A1 (en) | Quinoline and quinoxaline derivalives as kinase inhibitors | |
| UA109153C2 (xx) | Похідні хіноліну і хіноксаліну як інгібітори кінази | |
| TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
| EA202090141A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UCB BIOPHARMA SPRL (BE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25D | Requested change of name of applicant approved |
Owner name: UCB BIOPHARMA SRL (BE) |